PUBLICATIONS

Books and monographs published

Books Edited:


Book Chapters and Peer-Reviewed On-Line Publications:

In Press:


Published:


Monographs:
Singer C. Indicaciones y manejo de la toxina botulínica. Proceedings of the "Primer Ciclo de Cursos de Formación y Actualización en Neurología y Neurocirugía. Patología de las
Juried or Refereed Journals and Exhibitions

Accepted (In Press):


Published:


82-Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C.


Vieregge P, Slevin JT, Cambi F, MD, PhD; M.E. MacDonald, PhD; J.F. Gusella, PhD; Myers RH, GolbeLI. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age. The GenePD Study. NEUROLOGY 2006;67:2206–2210


60- Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson’s disease Urology 2006; 67(3): 447-51


11-Parkinson Study Group (Multicenter study including Singer C): A controlled trial of lazabemide


**Other works, publications and abstracts:**


**Abstracts**

**Under Review:**
Huntington Study Group PHAROS Investigators (Kevin Biglan MD, MPH corresponding author): Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington’s Disease by Gene Status: The Prospective Huntington’s Disease Observational At-Risk Study (PHAROS). Submitted on 9-04-2009 for presentation at the HDCRS.

In Press:


Published:

Parkinson Study Group. STEADY PD . Safety, Tolerability and Efficacy Assessmen of Isradipine CR for Parkinson Disease. Movement Disorders 2012; [supplement soon to be published].


Biglan KM, Zhao H, Oakes D, Kayson E, Shoulson I and the HSG PHAROS Investigators Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington’s Disease. Submitted 4-08 to ANA.


Huntington Study Group/PHAROS Investigators (Elise P. Kayson, University of Rochester, Rochester, NY). The welfare of research participants in the prospective Huntington at risk observational study (PHAROS). Mov Dis 2004; 19:9

Singer C, Papapetropoulos S, Gonzalez MA, Lieberman A, Roberts E. Rimantadine as an alternative to amantadine in Parkinson patients with severe leg edema secondary to amantadine: Case reports. Mov Disord 2004; 19 (Suppl 9):S244


Huntington Study Group/PHAROS Investigators (E. Kayson, primary author). Safety and feasibility of the Prospective Huntington At Risk Observational Study (PHAROS): A progress report. Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario, Canada and published in the program booklet of World Congress on Huntington's Disease, 2003 Abstract # 70, page 70.

Huntington Study Group/PHAROS Investigators (K. Biglan, primary author). Emerging cohort characteristics in the Prospective Huntington At Risk Observational Study (PHAROS). Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario, Canada and published in the program booklet of World Congress on Huntington's Disease, 2003 Abstract # 81, page 73.
Parkinson Study Group, Stern M. A Controlled Trial of Rasagiline in Parkinson’s Disease Patients with Levodopa-Related Motor Complications (PRESTO Study). Ann Neurol 2003; 54 (suppl 7): S27.


Farronay O, Singer C. Successful Use of Botulinum Toxin Type A in a child with hemifacial spasm. Mov Disord 2000


Adler CH, Singer C, Lew M, O'Brieb C, Pedder SCJ, Deptula D. Double-Blind, Placebo-


**Letters to the Editor**

**Under Review:**

Papapetropoulos S, Singer C, Sengun C Delgado S, Parkinsonism/dystonia syndrome secondary to multiple sclerosis with anti-basal ganglia antibodies. (Letter to the Editor) (Submitted to Mov Disorder 4-4-08).

**In Press:**

Scanlon KB, Katzen HL, Levin BE, Singer C, Papapetropoulos S. A formula for the conversion of UPDRS-III scores to Hoehn & Yahr stage (accepted PDRD 2007).


**Published:**


Papapetropoulos S, Singer C: Primary writing tremor and writer's cramp are different nosologic entities. J Neurol Neurosurg Psychiatry 2004;75(12):e-letter.


**Scientific Presentations at National and International Meetings.**

**Under Review.**

Huntington Study Group PHAROS Investigators (Kevin Biglan MD, MPH corresponding author): Longitudinal Analysis of the UHDRS in Individuals At-Risk for Huntington's Disease by Gene Status: The Prospective Huntington’s Disease Observational At-Risk Study (PHAROS). Submitted on 9-04-2009 for presentation at the HDCRS.

**Presented:**


Singer C, Pappert E, Hanschmann, Fernandez H for the XEOMIN® US Cervical Dystonia Study Group. IncobotulinumtoxinA (NT201, Xeomin®) administered at flexibleintervals of 6-20 weeks in subjects with cervical dystonia. Presented at the 16 International Congress of Parkinson’s
Disease and Movement Disorders, June 17-21, Dublin, Ireland.


Solitary Parkinsonian Signs May Herald the Eventual Appearance of Parkinson Disease. Poster session at the 61st Annual Meeting of the American Academy of Neurology, April 25-May 2nd, 2009. (Accepted)


Papapetropoulos S, Friedman J, Blackstone C, Kleiner GI, Sengun C, Singer C. A progressive, fatal dystonia-parkinsonism syndrome in a patient with primary immunodeficiency receiving chronic IVIG therapy. Poster presentation at the 11th International Congress of Parkinson's Disease and Movement Disorders, June 2007, Istambul, Turkey.


Singer C, Papapetropoulos S, Spielholz NI. Primary writing tremor successfully treated with botulinum toxin: report of two cases. [Poster Presentation]. 9th International Congress of Parkinson’s Disease and Movement Disorders, March 5-8, 2005, New Orleans, La.


Singer C, Papapetropoulos S, Gonzalez MA, Lieberman A, Roberts E. Rimantadine as an alternative to amantadine in Parkinson patients with severe leg edema secndary to amatadine: Case reports. [Poster Presentation]. 8th International Congress of Parkinson’s Disease and Movement Disorders, June 13-17, 2004, Rome, Italy.


Huntington Study Group/PHAROS Investigators (E. Kayson, primary author). Safety and feasibility of the Prospective Huntington At Risk Observational Study (PHAROS): A progress report. Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario, Canada and published in the program booklet of World Congress on Huntington's Disease, 2003 Abstract # 70, page 70.

Huntington Study Group/PHAROS Investigators (K. Biglan, primary author). Emerging cohort characteristics in the Prospective Huntington At Risk Observational Study (PHAROS). Accepted for presentation at the World Congress on Huntington's Disease, August 16-19, 2003, Toronto, Ontario, Canada and published in the program booklet of World Congress on Huntington's Disease, 2003 Abstract # 81, page 73.


Verma A, Steele J, Singer C. Botulinum Toxin Improves Sialorrhea and Quality of Life in Bulbar


Singer C, Shulman LM, Weiner WJ: Botulinum toxin injection to cervical muscles involved in generalized dystonia. Poster presentation at the International Conference on Botulinum Toxin:


